Indaptus Therapeutics, Inc. Prepaid Expense and Other Assets, Current
Indaptus Therapeutics, Inc. (INDP) had Prepaid Expense and Other Assets, Current of $434.14 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-13
- 2026-06-30: Prepaid Expense and Other Assets, Current $434.14K.
- 2026-03-31: Prepaid Expense and Other Assets, Current $683.22K.
- 2025-12-31: Prepaid Expense and Other Assets, Current $802.54K.
- 2025-09-30: Prepaid Expense and Other Assets, Current $613.35K.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $434.14K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $683.22K 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $802.54K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $613.35K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $255.36K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $1.07M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $831.58K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $248.74K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $186.73K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $551.03K 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $633.16K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $879.52K 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $180.78K 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $470.75K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $811.43K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $1.13M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $260.88K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $741.95K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $1.11M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $1.40M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $801.00K 10-Q · filed 2021-08-16 | |
| 2020-12-31 | $94.50K 10-K · filed 2022-03-21 | $297.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |